Ranolazine for the management of coronary artery disease

Clinical Therapeutics

Volumn 28, Issue 12, 2006, Pages 1996-2007

  Cheng, Judy W M ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ranolazine, stable angina, coronary artery disease

Indexed keywords

AMLODIPINE; DILTIAZEM; ISOSORBIDE; METOPROLOL; PLACEBO; RANOLAZINE; VERAPAMIL;

ANGINA PECTORIS; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DATA BASE; DIZZINESS; DRUG CONTRAINDICATION; DRUG POTENCY; EXERCISE; HEADACHE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MEDLINE; NAUSEA; PEER REVIEW; QT INTERVAL; REVIEW; ST SEGMENT DEPRESSION; UNITED STATES;

ACETANILIDES; ANGINA PECTORIS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; PIPERAZINES; TREATMENT OUTCOME;

EID: 33846804167     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.12.009     Document Type: Review

References (28)

1. American Heart Association. Heart disease and stroke statistics 2006 updates. Circulation 113 (2006) 85-151
2. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to update the 1999 guidelines for the management of patients with chronic stable angina) (2002). http://www.americanheart.org/downloadable/heart/1044991838085StableAnginaNewFigs.pdf
3. Holubkov R., Laskey W.K., Haviland A., et al., NHLBI Dynamic Registry Investigators. Angina 1 year after percutaneous coronary intervention: A report from the NHLBI Dynamic Registry. Am Heart J 144 (2002) 826-833
4. Hueb W., Soares P.R., Gersh B.J., et al. The medicine, angioplasty, or surgery study (MASS-II): A randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: One-year results. J Am Coll Cardiol 43 (2004) 1743-1751
5. Lopaschuk G.D., Wambolt R.B., and Barr R.L. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 264 (1993) 135-144
6. Abrams J. Chronic stable angina. N Engl J Med 352 (2005) 2524-2533
7. Theroux P. Protection of the myocardial cell during ischemia. Am J Cardiol 83 (1999) 3G-9G
8. Stanley W.C., and Chandler M.P. Energy metabolism in the normal and failing heart: Potential for therapeutic interventions. Heart Fail Rev 7 (2002) 115-130
9. Hutter J.F., Piper H.M., and Spieckerman P.G. Effect of fatty acid oxidation on efficiency of energy production in rat heart. Am J Physiol 249 (1985) H723-H728
10. Lopaschuk G.D., and Stanley W.C. Glucose metabolism in the ischemic heart. Circulation 95 (1997) 313-315
11. Ranexa (ranolazine) [product information] (November 18, 2006)
12. Gaffney S.M. Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy 26 (2006) 135-142
13. MacInnes A., Fairman D.A., Binding P., et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 93 (2003) e26-e32
14. Makielski J.C., and Valdivia C.R. Ranolazine and late cardiac sodium current-a therapeutic target for angina, ar rhythmia and more?. Br J Pharmacol 148 (2006) 4-6
15. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 45 (2006) 469-491
16. Jerling M., and Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ra nolazine. Clin Pharmacol Ther 78 (2005) 288-297
17. Abdallah H., and Jerling M. Effect of hepatic impairment on the multipledose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 45 (2005) 802-809
18. Jerling M., Huan B.L., Leung K., et al. Studies to investigate the pharmacokinetic interactions between ra nolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.). Clin Pharmacol 45 (2005) 422-433
19. Thadani U., Ezekowitz M., Fenney L., Chiang Y.K., and Ranolazine Study Group. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation 90 (1994) 726-734
20. Pepine C.J., Wolff A.A., and Ranolazine Study Group. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 84 (1999) 46-50
21. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004) 1375-1382
22. Chaitman B.R., Pepine C.J., Parker J.O., et al., Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 291 (2004) 309-316
23. Rousseau M.F., Pouleur H., Cocco G., and Wolff A.A. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 95 (2005) 311-316
24. Stone P.H., Gratsiansky N.A., Blokhin A., and ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48 (2006) 566-575
25. Timmis A.D., Chaitman B.R., and Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 27 (2006) 42-48
26. Prescription price checker. Available at: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=67159011203&trx=1Z5006. Accessed November 18, 2006.
27. Poelzing S., Forleo C., Samodell M., et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation 114 (2006) 368-376
28. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., et al., MERLIN-TIMI 36 Investigators. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndrome (MERLIN) TIM 136 trial. Am Heart J 151 (2006) 1186.e1-1186.e9